UBS analyst Marc Goodman raised his price target for Alkermes to $41 from $34 after adding ALKS 5461 back into his model. Management remains optimistic about the asset to treat depression, Goodman tells investors in a research note. The analyst, however, remains skeptical that the FORWARD-5 study will be positive and that the drug can be approved without two positive Phase 3 studies. He raised his 2017 earnings per share estimate to 44c from 30c and for 2018 to 85c from 50c. Goodman maintains a Neutral rating on Alkermes, wanting a better risk/reward profile for the shares.